GSKC Anleihen
Unten befindet sich eine Liste von GSK PLC CEDEAR EACH REPR 1/4 ADR Unternehmensanleihen. Investoren entscheiden sich oft für Unternehmensanleihen, weil sie eine gesteigerte Stabilität zu Zeiten von erheblichen Marktvolatilitäten bieten. Sehen Sie sich die Preise, Renditen und weitere Daten an. Entdecken Sie eine zuverlässige Investition.
Symbol | YTM % | Volumen | Preis % | Coupon % | Verfallsdatum | Ausstehend | Nennwert | Min. Anlagebetrag | Emittent |
|---|---|---|---|---|---|---|---|---|---|
| 117RIGLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45 | 5,57% | 8,46 K | 82,51% | 4,25% | 2045-12-18 | 370,786 M GBP | 1.000,00 GBP | 100.000,00 GBP | GlaxoSmithKline Capital Plc |
| 883GIGLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042 | 5,31% | 0 | 99,28% | 5,25% | 2042-04-10 | 477,816 M GBP | 1.000,00 GBP | 50.000,00 GBP | GlaxoSmithKline Capital Plc |
| 771ZCGLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39 | 5,25% | 0 | 111,75% | 6,38% | 2039-03-09 | 631,3 M GBP | 1.000,00 GBP | 50.000,00 GBP | GlaxoSmithKline Capital Plc |
| GGSK3981911GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043 | 5,24% | 15 K | 87,07% | 4,20% | 2043-03-18 | 500 M USD | 1.000,00 USD | 2.000,00 USD | GlaxoSmithKline Capital, Inc. |
| GGSK.GJGlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038 | 5,21% | 5,11 M | 111,65% | 6,38% | 2038-05-15 | 2,75 B USD | 1.000,00 USD | 2.000,00 USD | GlaxoSmithKline Capital, Inc. |
| XXS217060907GLAXOSM.CAP. MTN 20/35MTN | 4,92% | 0 | 72,53% | 1,63% | 2035-05-12 | 750 M GBP | 1.000,00 GBP | 100.000,00 GBP | GlaxoSmithKline Capital Plc |
| AAG99GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033 | 4,73% | 0 | 103,93% | 5,25% | 2033-12-19 | 574,166 M GBP | 1.000,00 GBP | 1.000,00 GBP | GlaxoSmithKline Capital Plc |
| 772WIGLAXOSMITHKLINE CAPITAL INC 5.375% GTD SNR NTS 15/04/2034 | 4,69% | 8 K | 105,28% | 5,38% | 2034-04-15 | 500 M USD | 1.000,00 USD | 1.000,00 USD | GlaxoSmithKline Capital, Inc. |
| UUS377373AH8GLAXOSM.CAP. 19/29 | 4,60% | 0 | 94,93% | 3,38% | 2029-06-01 | 1 B USD | 1.000,00 USD | 2.000,00 USD | GlaxoSmithKline Capital Plc |
| UUS377372AN7GLAXOSMITHKLINE CAP.18/28 | 4,53% | 0 | 97,89% | 3,88% | 2028-05-15 | 1,75 B USD | 1.000,00 USD | 2.000,00 USD | GlaxoSmithKline Capital, Inc. |
| XXS217060184GLAXOSM.CAP. MTN 20/28MTN | 4,43% | 0 | 88,53% | 1,25% | 2028-10-12 | 750 M GBP | 1.000,00 GBP | 100.000,00 GBP | GlaxoSmithKline Capital Plc |
| GGSK4632357GlaxoSmithKline Capital, Inc. 3.625% 15-MAY-2025 | 3,97% | 228 K | 99,66% | 3,63% | 2025-05-15 | 1 B USD | 1.000,00 USD | 2.000,00 USD | GlaxoSmithKline Capital, Inc. |
| GGX5CGLAXOSM.CAP. MTN 05/25 | 3,32% | 0 | 100,67% | 4,00% | 2025-06-16 | 750 M EUR | 1.000,00 EUR | 1.000,00 EUR | GlaxoSmithKline Capital Plc |
| XXS255381776GSK CAP B.V. 22/32 MTN | 3,04% | 0 | 100,62% | 3,13% | 2032-11-28 | 700 M EUR | 1.000,00 EUR | 100.000,00 EUR | GSK Capital BV |
| XXS182282979GLAXOSM.CAP. MTN 18/30MTN | 2,80% | 0 | 94,62% | 1,75% | 2030-05-21 | 750 M EUR | 1.000,00 EUR | 100.000,00 EUR | GlaxoSmithKline Capital Plc |
| XXS255381768GSK CAP B.V. 22/27 MTN | 2,67% | 0 | 100,98% | 3,00% | 2027-11-28 | 500 M EUR | 1.000,00 EUR | 100.000,00 EUR | GSK Capital BV |
| XXS168152035GLAXOSM.CAP. MTN 17/29 | 2,64% | 0 | 94,25% | 1,38% | 2029-09-12 | 500 M EUR | 1.000,00 EUR | 100.000,00 EUR | GlaxoSmithKline Capital Plc |
| GGX5BGLAXOSM.CAP. MTN 17/26 | 2,57% | 0 | 97,18% | 1,00% | 2026-09-12 | 700 M EUR | 1.000,00 EUR | 100.000,00 EUR | GlaxoSmithKline Capital Plc |
| XXS182282812GLAXOSM.CAP. MTN 18/26MTN | 2,53% | 0 | 98,09% | 1,25% | 2026-05-21 | 1 B EUR | 1.000,00 EUR | 100.000,00 EUR | GlaxoSmithKline Capital Plc |
| XXS114760579GLAXOSM.CAP. MTN 14/24 | 1,46% | 0 | 99,92% | 1,38% | 2024-12-02 | 1 B EUR | 1.000,00 EUR | 100.000,00 EUR | GlaxoSmithKline Capital Plc |
| 117RNGLAXOSMITHKLINE CAPITAL PLC 3.375% GTD SNR EMTN 20/12/2027 | −0,52% | 0 | 112,19% | 3,38% | 2027-12-20 | 307,77 M GBP | 1.000,00 GBP | 100.000,00 GBP | GlaxoSmithKline Capital Plc |
| AAQ72GLAXOSMITHKLINE CAPITAL PLC 0.883% GTD SNR EMTN 21/09/20 | — | — | — | 0,88% | 2028-09-21 | 42,5 B JPY | 100.000.000,00 JPY | — | GlaxoSmithKline Capital Plc |